Neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, age-related macular degeneration and Huntington’s disease involve different regions of the central nervous system yet they share key defects in cellular pathways. By selectively modulating a central cellular damage response pathway, Cognition’s drug candidates stop the toxic effects of age-related damage on brains cells that lead to neurodegeneration. By facilitating the normal function of this pathway, neurons in the brain and eye may function normally and avoid the effects of neurodegeneration.
A number of eye diseases, including dry AMD and geographic atrophy (GA), a more advanced form of the disease, are characterized by oxidative stress and an age-related buildup of toxic proteins that cause damage to retinal cells. CT1812 may remove these toxic proteins and restore downstream processes.
The age-related buildup of stressors such as oligomeric forms of proteins (Aβ, α-synuclein, huntingtin), reactive oxygen species and inflammatory agents drive many neurodegenerative diseases. We hypothesize that our our candidates have disease-modifying effects on a number of neurodegenerative and neuro-ophthalmic conditions.
Cognition’s biological discovery platform, through which CT1812 was identified, is based on unbiased phenotypic screens in the target cell population of mature primary neurons.
Pittsburgh, PA, January 5, 2021 – Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that President and CEO Lisa Ricciardi is participating in the Biotech Showcase™ 2021 conference and
PITTSBURGH, October 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Brett P. Monia, Ph.D. to its board of directors. Dr. Monia is a
PITTSBURGH, October 19, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that a peer-reviewed manuscript, entitled, “Icelandic Mutant Human Amyloid-β 1-42 Peptide Forms Fewer Oligomers with Lower
Cognition Therapeutics appoints Jack A. Khattar, founder and current CEO of Supernus Pharmaceuticals, to its board of directors. Mr. Khattar has expertise in building pipelines through organic growth and strategic acquisitions.
